233 related articles for article (PubMed ID: 26708112)
1. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
[TBL] [Abstract][Full Text] [Related]
2. New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1.
Costa CCP; Boechat N; Bastos MM; da Silva FC; Marttorelli A; Souza TML; Baptista MS; Hoelz LVB; Cafffarena ER
Curr Top Med Chem; 2018; 18(17):1494-1505. PubMed ID: 30370848
[TBL] [Abstract][Full Text] [Related]
3. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
Braz VA; Holladay LA; Barkley MD
Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
[TBL] [Abstract][Full Text] [Related]
5. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
6. Development of nonnucleoside HIV reverse transcriptase inhibitors.
Tucker TJ; Lumma WC; Culberson JC
Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
[No Abstract] [Full Text] [Related]
7. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
8. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
[TBL] [Abstract][Full Text] [Related]
9. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
Famiglini V; Silvestri R
Molecules; 2016 Feb; 21(2):. PubMed ID: 26891289
[TBL] [Abstract][Full Text] [Related]
10. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
11. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
Xu ZQ; Buckheit RW; Stup TL; Flavin MT; Khilevich A; Rizzo JD; Lin L; Zembower DE
Bioorg Med Chem Lett; 1998 Aug; 8(16):2179-84. PubMed ID: 9873509
[TBL] [Abstract][Full Text] [Related]
13. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A
Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
16. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
[TBL] [Abstract][Full Text] [Related]
18. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
19. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
20. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.
Motakis D; Parniak MA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1851-6. PubMed ID: 12019100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
